FDA 483 - William A. Gahl, MD, PhD - December 19, 2024

An FDA inspection of NIH / NIH Clinical Center in Bethesda, MD, identified one observation related to their role as a Sponsor-Investigator. The firm failed to monitor the progress of an investigation conducted under an IND, specifically lacking documentation of clinical monitoring throughout the study. This indicates a deficiency in oversight of clinical trial activities.